Key result
IV alteplase increases early thrombus resolution ~23% after ischemic stroke regardless of location.
RCT
Masked raters
Randomized controlled
Yes
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To investigate whether the location and extent of the CT hyperdense artery sign (HAS) at presentation affects response to IV alteplase in the randomized controlled Third International Stroke Trial (IST-3). METHODS: All prerandomization and follow-up (24-48 hours) CT brain scans in IST-3 were assessed for HAS presence, location, and extent by masked raters. We assessed whether HAS grew, persisted, shrank, or disappeared at follow-up, the association with 6-month functional outcome, and effect of alteplase. IST-3 is registered (ISRCTN25765518). RESULTS: HAS presence (vs absence) independently predicted poor 6-month outcome (increased Oxford Handicap Scale [OHS]) on adjusted ordinal regression analysis (odds ratio [OR] 0.66, p < 0.001). Outcome was worse in patients with more (vs less) extensive HAS (OR 0.61, p = 0.027) but not in proximal (vs distal) HAS (p = 0.420). Increasing age was associated with more HAS growth at follow-up (OR 1.01, p = 0.013). Treatment with alteplase increased HAS shrinkage/disappearance at follow-up (OR 0.77, p = 0.006). There was no significant difference in HAS shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive HAS (p = 0.516 and p = 0.580, respectively). There was no interaction between presence vs absence of HAS and benefit of alteplase on 6-month OHS (p = 0.167). CONCLUSIONS: IV alteplase promotes measurable reduction in HAS regardless of HAS location or extent. Alteplase increased independence at 6 months in patients with and without HAS. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients within 6 hours of ischemic stroke with a CT hyperdense artery sign, IV alteplase reduced intra-arterial hyperdense thrombus.
No takes yet. Share an insight, caveat, or question.
Mair et al. (2015) conducted an RCT in Ischemic stroke with CT hyperdense artery sign. IV alteplase vs. Control (no alteplase) was evaluated on CT hyperdense artery sign (HAS) shrinkage or disappearance at 24-48 hour follow-up (OR 0.77, p=0.006). IV alteplase increased CT hyperdense artery sign shrinkage or disappearance at 24-48 hours after ischemic stroke regardless of thrombus location or extent.
Synapse has enriched 10 related papers. Consider them for comparative context: